Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/2171
Share/Export:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
DC FieldValueLanguage
dc.contributor.authorGarcía-Jiménez, Custodia-
dc.contributor.authorSantisteban, Pilar-
dc.date.accessioned2007-11-15T15:40:42Z-
dc.date.available2007-11-15T15:40:42Z-
dc.date.issued2007-
dc.identifier.citationArquivos brasileiros de Endocrinologia e Metabologia 51(5): 654-671 (2007)en_US
dc.identifier.issn0004-2730-
dc.identifier.urihttp://hdl.handle.net/10261/2171-
dc.description.abstractThyroid cancers are the most frequent endocrine neoplasms and mutations in the thyrotropin receptor (TSHR) are unusually frequent. Here we present the state-of-the-art concerning the role of TSHR in thyroid cancer and discuss it in light of the cancer stem cell theory or the classical view. We briefly review the gene and protein structure updating the cancer related TSHR mutations database. Intriguingly, hyperfunctioning TSHR mutants characterise differentiated cancers in contrast to undifferentiated thyroid cancers which very often bear silenced TSHR. It remains unclear whether TSHR alterations in thyroid cancers play a role in the onset or they appear as a consequence of genetic instability during evolution, but the presence of functional TSHR is exploited in therapy. We outline the signalling network build up in the thyrocyte between TSHR/PKA and other proliferative pathways such as Wnt, PI3K and MAPK. This networks integrity surely plays a role in the onset/evolution of thyroid cancer and needs further research. Lastly, future investigation of epigenetic events occurring at the TSHR and other loci may give better clues for molecular based therapy of undifferentiated thyroid carcinomas. Targeted demethylating agents, histone deacetylase inhibitors combined with retinoids and specific RNAis may help treatment in the future.en_US
dc.description.sponsorshipWe are grateful to grants URJC-CM-2006-BIO-0522 (to CG-J) and BFU 2004-03 169, and FIS PI 041216, PI 042374, RD06 0020 0060 (to PS) for supporting our work.en_US
dc.language.isoengen_US
dc.publisherFederação Brasileira de Sociedades de Endocrinologia e Metabologiaen_US
dc.rightsopenAccessen_US
dc.subjectThyrotropinen_US
dc.subjectCanceren_US
dc.subjectSignallingen_US
dc.subjectMAPKen_US
dc.subjectPI3Ken_US
dc.subjectPKAen_US
dc.subjectWnten_US
dc.subjectThyroiden_US
dc.subjectNISen_US
dc.titleTSH signalling and canceren_US
dc.title.alternativeSinalização de TSH e cânceren_US
dc.typeartículoen_US
dc.description.peerreviewedPeer revieweden_US
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.languageiso639-1en-
item.openairetypeartículo-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat
tsh.pdf189,51 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

514
checked on Jun 25, 2022

Download(s)

354
checked on Jun 25, 2022

Google ScholarTM

Check


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.